Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children

Ulises De la Cruz-Mosso a, José Francisco Muñoz-Valle b, Aralia Berenice Salgado-Bernabé a, Natividad Castro-Alarcón c, Lorenzo Salgado-Goytia c, José Sánchez-Corona d, Silvia Esperanza Flores-Martínez d, Isela Parra-Rojas c,

a BSc. Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, Mexico
b PhD. Instituto de Investigación en Ciencias Biomédicas, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
c PhD. Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, Mexico
d PhD. División de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, Mexico

Received 1 October 2012; accepted 10 January 2013
Available online 18 July 2013

KEYWORDS
PAI-1 gene; Polymorphisms; Body adiposity; Insulin resistance

Abstract
Objective: To assess whether the -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is associated with obesity and insulin resistance in Mexican children.
Methods: A cross-sectional study was performed in 174 children, 89 with normal-weight and 85 with obesity, aged from 6 to 13 years. All children were from state of Guerrero, and recruited from three primary schools in the city of Chilpancingo, state of Guerrero, Mexico. Insulin levels were determined by immunoenzymatic assay. The homeostasis model assessment was used to determine insulin resistance. The -675 4G/5G polymorphism in PAI-1 was analyzed by polymerase chain reaction-restriction fragment length polymorphism.
Results: The prevalence of insulin resistance in the obese group was higher (49.41%) than in the normal-weight group (16.85%). The 4G/5G PAI-1 polymorphism was found in Hardy Weinberg equilibrium. The 4G/5G genotype contributed to a significant increase in waist-hip ratio ($\beta = 0.02, p = 0.006$), waist circumference ($\beta = 4.42, p = 0.009$), and subscapular skinfold thickness ($\beta = 1.79, p = 0.04$); however, it was not related with insulin resistance.
Conclusion: The -675 4G/5G genotype of PAI-1 gene was associated with increase of body adiposity in Mexican children.

© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.
Este é um artigo Open Access sob a licença de CC BY-NC-ND

0021-7557 © 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
http://dx.doi.org/10.1016/j.jped.2013.01.004
Introduction

Obesity is a complex, multifactorial chronic disease, frequently associated with insulin resistance, that appears to be the central characteristic to the pathogenesis of diabetes mellitus type 2; these metabolic disorders have been associated with increased plasminogen activator inhibitor-1 (PAI-1) levels in circulation.1

PAI-1 is the main inhibitor in the plasminogen activation system (PAS), which comprises an inactive proenzyme (plasminogen) that can be converted into its active form plasmin by the action of physiological plasminogen activators (PAs).2 Plasmin is the main enzyme that degrades fibrin into soluble products. Under physiological conditions PAI-1, is released into the circulation and into the extracellular space by certain cells, such as hepatocytes, smooth muscle cells, spleen cells, myocytes, adipocytes, monocytes, macrophages, and platelets, which are the main source of PAI-1.3,4 In pathological conditions, other tissues, such as tumor and endothelial cells secrete a large amount of PAI-1, mainly in response to upregulation by inflammatory cytokines; thus, PAI-1 is regarded as a marker in the course of inflammatory processes.4,5,6 The increase of PAI-1 levels in plasma is associated with risk factors such as obesity, glucose intolerance, hypertension, insulin resistance, and metabolic syndrome.4,8-10

Over 180 single nucleotide polymorphisms (SNPs) have been described in the PAI-1 gene. The -675 4G/5G polymorphism is characterized by an insertion/deletion of a single nucleotide guanine at position -675 of the promoter of PAI-1 gene.11 This polymorphism has been associated with high levels of PAI-1, obesity, hypertension, dyslipidemia, glucose intolerance, and insulin resistance.12 In a white European population it has been reported that subjects who are homozygous for the 4G allele (4G/4G genotype) have plasma concentrations of PAI-1 approximately 25% higher than subjects who are homozygous for the 5G allele (genotype 5G/5G).13 In another study, the -675 4G/5G polymorphism influenced the development of a state of insulin resistance and obesity, indicating that this polymorphism may be a marker of genetic susceptibility for these diseases.1,12 Therefore, this study was designed to assess whether the -675 4G/5G PAI-1 gene polymorphism is associated with obesity and insulin resistance in Mexican children.

Methods

A cross-sectional study was performed in 174 children, 89 with normal weight and 85 with obesity, aged between 6 and 13 years. All children were from the state of Guerrero, Mexico, and recruited from three primary schools in the city of Chilpancingo, Mexico. An informed consent was obtained from all parents before enrollment of children in the study. Approval for the study was obtained from the Research Ethics Committee of the University of Guerrero according to the ethical guidelines of the Declaration of Helsinki.

Body weight was determined using a Tanita body composition monitor (Tanita BC-533 = Arlington, USA), and height was measured to the nearest 0.1 cm using a stadiometer (Seca - Hamburg, Germany). Body circumferences were measured in duplicate using a diameter tape accurate to within ± 0.1 cm (Seca 201 - Hamburg, Germany). Waist circumference was measured at the level of the umbilicus and the superior iliac crest. Hip circumference was measured at the maximum point below the waist, without compressing.
the skin. The thickness of four skinfolds was measured to the
nearest 0.1 mm, in duplicate, using a skinfold caliper (Dyna-
tronics Co - Salt Lake City, USA): triceps, biceps, subcapsular,
and suprailiac. The duplicate measures were averaged. The
classification of obesity was made using the 2000 Centers for
Disease Control and Prevention growth charts, which defined
normal weight as the 5th to 85th percentiles, and obesity as
≥95th percentile.

Blood samples were obtained from antecubital venipunc-
ture after overnight fast. Serum glucose was analyzed with
semi-automated equipment (COBAS MIRA). Insulin levels
were determined by immunoenzymatic assay (GenWay INS-
EASIA kit). The homeostasis model assessment was used to
determine insulin resistance (IR) in children; this score was
calculated with the following formula: fasting serum insulin
(μU/mL) x fasting plasma glucose (mmol/L)/22.5. Insulin
resistance was defined as a homeostasis model assessment
for insulin resistance (HOMA-IR) above the 75th percentile
for all children (HOMA-IR ≥ 2.4).

The extraction of genomic DNA (gDNA) was per-
formed from leukocytes obtained from whole blood
samples, according to the Miller method. The -675
4G/5G PAI-1 gene polymorphism was screened by the
polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP) method, using following
primers: 5′CACAGAGAGTCTGGCCACGT3′ (forward),
and 5′CCAACAGGACTCTTGGTCT3′ (reverse). PCR
was carried out in a final volume of 25 μL containing 1 μg of
dNA, 0.06 μM of each oligonucleotide, 1.25 U/μL Taq DNA
polymerase, supplied buffer enzyme 1X, 1.5 mM MgCl2,
and 0.1 mM of each dNTP (Invitrogen™ life technologies).
PCR was performed by initial denaturation at 94°C during
3 min, 30 cycles of amplification at 94°C for 30 s for
denaturation, at 60°C during 30 s for annealing, and at
72°C during 30 s for extension. Finally, 72°C during 1 min
was used for end extension, resulting in a fragment of 99 bp
for the 5G or 98 bp for the 4G. These were analyzed on a 6%
polyacrylamide gel (Invitrogen™ life technologies) stained
with silver nitrate. Amplified fragments were digested for
2 h and 30 min at 55°C with 3 U of Bst I (New England Bio-
labs) restriction enzyme. Afterwards, restriction fragments
were analyzed by electrophoresis on 6% polyacrylamide
gel (Invitrogen™ life technologies) stained with silver
nitrate. PAI-1 genotyping was done in duplicate in all cases
(Fig. 1). To confirm the results, were random selected a
few genotypes and analyzed for sequencing.

The statistical analysis was performed using the
statistical software STATA v. 9.2. For the descriptive anal-
ysis, nominal variables were expressed as frequencies,
continuous variables normally-distributed as mean and
standard deviation, and those not normally-distributed
were expressed as medians and 5th and 95th percentiles.
The chi-squared test was used to compare proportions between
groups (normal weight and obese children), and Student’s
t-test and/or Mann-Whitney test were used to compare
quantitative measurements between groups. Genotype and
allele frequencies for the polymorphism -675 4G/5G PAI-1
gene were determined by direct counting, and the sig-
nificance of the differences between the biochemical and
anthropometric parameters for each genotype was deter-
mined using ANOVA and by the Kruskal-Wallis test; the
chi-squared test was used to evaluate the Hardy-Weinberg
equilibrium. To evaluate the effect of polymorphism, linear
regression models were used. Differences were considered
statistically significant when p < 0.05.

Results

The comparison of the clinical and anthropometric vari-
ables between both groups revealed, in the obese group, a
significant increase of glucose and insulin levels, measures
of central and peripheral adiposity, as well as systolic and
diastolic blood pressures. The prevalence of insulin resis-
tance the in obese group was 49.41%, versus the 16.85% of
the group with normal-weight (Table 1).
Table 1  Clinical and biochemical characteristics in normal weight and obese children.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Normal weight children (n = 89)</th>
<th>Obese children (n = 85)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>9 (6–12)</td>
<td>9 (6–11)</td>
<td>0.66</td>
</tr>
<tr>
<td><strong>Gender (%)</strong></td>
<td></td>
<td></td>
<td>0.12</td>
</tr>
<tr>
<td>Male</td>
<td>40 (44.94)</td>
<td>48 (56.47)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>49 (55.06)</td>
<td>37 (43.53)</td>
<td></td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>28 (19.2–41.8)</td>
<td>44.2 (27.4–64.9)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Height (cm)</strong></td>
<td>130.9 ± 10.96</td>
<td>135.9 ± 11.66</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>16.3 (13.9–19.7)</td>
<td>23.4 (18.8–29.25)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Waist-hip-ratio</strong></td>
<td>0.87 (0.8–0.95)</td>
<td>0.9 (0.8–1)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Waist circumference (cm)</strong></td>
<td>62 (52–73)</td>
<td>80 (65–94)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Hip circumference (cm)</strong></td>
<td>70 (61–82)</td>
<td>85 (68.5–100)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Arm circumference (cm)</strong></td>
<td>19 (15–23)</td>
<td>24.5 (20.5–32)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Biceps skinfold (mm)</strong></td>
<td>13.53 ± 4.03</td>
<td>17.84 ± 4.19</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Triceps skinfold (mm)</strong></td>
<td>12 (7.5–18)</td>
<td>18 (11.5–22)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Subscapular skinfold (mm)</strong></td>
<td>9.5 (5–17)</td>
<td>18.5 (11.5–24.5)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Suprailiac skinfold (mm)</strong></td>
<td>15.11 ± 4.56</td>
<td>21.33 ± 4.85</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Glucose (mg/dL)</strong></td>
<td>95 (72–109)</td>
<td>98 (81–109)</td>
<td>&lt; 0.05</td>
</tr>
<tr>
<td><strong>Insulin (μU/mL)</strong></td>
<td>4.7 (0.55–13.58)</td>
<td>9.39 (1.25–27.53)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>HOMA-IR</strong></td>
<td>1.1 (0.12–3.12)</td>
<td>2.2 (0.24–6.78)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td><strong>Insulin resistance</strong></td>
<td></td>
<td></td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Yes</td>
<td>15 (16.85)</td>
<td>42 (49.41)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>74 (83.15)</td>
<td>43 (50.59)</td>
<td></td>
</tr>
</tbody>
</table>

BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; SD, standard deviation.

* Data provided as median and 5th and 95th; Mann-Whitney test.

*b Data provided as n and percentage; Chi-squared test.

*c Data provided as mean±SD; Student’s t-test.

The 4G/5G PAI-1 polymorphism was found in Hardy Weinberg equilibrium ($\chi^2 = 0.95$, $p = 0.4$). The distribution of genotype and allele frequencies of -675 4G/5G PAI-1 polymorphism was as follows: in the obese group, 8.24% 4G/4G, 49.41% 4G/5G and 42.35% 5G/5G, for 4G allele 32.94% and 5G allele 67.06%, whereas in the normal-weight group, 8.99% 4G/4G, 34.83% 4G/5G and 56.18% 5G/5G, for 4G allele 26.40% and 5G allele 73.60%. In both groups, the 5G/5G genotype and the 5G allele were the most frequently identified. The comparison between both groups showed no significant differences in genotype ($\chi^2 = 3.91$, $p = 0.14$) and allele frequencies ($\chi^2 = 1.78$, $p = 0.18$).

Clinical and biochemical variables were compared by genotypes of -675 4G/5G polymorphism. Carriers of the 4G/5G genotype showed a significant increase in waist-hip ratio ($p = 0.02$), and trends for the increase in waist circumference ($p = 0.08$) and subscapular skinfold thickness ($p = 0.09$) compared with carriers of genotypes 4G/4G and 5G/5G (Table 2).

To estimate the contribution of polymorphism to anthropometric and metabolic variables, multiple linear regression models were used. After adjustment for age and gender, it was determined that the 4G/5G genotype contributed to a significant increase in waist-hip ratio ($\beta = 0.02$, $p = 0.006$), waist circumference ($\beta = 4.42$, $p = 0.009$), and subscapular skinfold thickness ($\beta = 1.79$, $p = 0.04$) (Table 3). However, no relationship with insulin levels, HOMA-IR, or insulin resistance was found (data not shown).

**Discussion**

It is currently known that insulin resistance is an important predictor of diabetes mellitus type 2, and is one of the main factors involved in the development of insulin resistance related to increased adipose tissue and its release of adipokines; a protein that is secreted by adipocytes in great amounts is PAI-1.13 Previous studies in other populations to investigate the contribution of PAI-1 polymorphism with obesity and insulin resistance have reported inconsistent results.14 In the present study, it was found that the -675 4G/5G polymorphism is related with measures of body adiposity, but not with insulin resistance, in Mexican children.

The results indicate that this sample of obese children had increased glucose and insulin levels, measures of central and peripheral adiposity, and a high prevalence of insulin resistance (49.41%); however, 16.85% of normal-weight children had insulin resistance.

Regarding the genotype and allele frequency, it was observed that this polymorphism is inversely distributed compared to those reported in white populations, in which the 4G/4G genotype (> 25%) was more common than the 5G/5G genotype. In the present population, the 5G/5G genotype was more frequent (42.35%), and the 4G/4G genotype was less common (8.24%). These differences can be attributed to the racial influence, which may be related to the genetic background of the population. It is known...
that the Mexican population originated from a mixture of European and African populations with Amerindian groups, giving origin to the Mexican mestizo population, which has a great genetic diversity in the distribution of this and other polymorphisms.  

This study described, for first time in Mexican children, that -675 4G/5G polymorphism in the PAI-1 gene is not associated with insulin resistance, but with increased body adiposity, determined by increase in the waist-hip ratio, waist circumference, and subscapular skinfold thickness, in carriers of 4G/5G genotype. In contrast, some authors have reported a relationship between the 4G/4G genotype with insulin resistance and increased adipose tissue in white populations, where the 4G allele is considered the risk allele, since it was associated with high plasma levels of PAI-1 due to the lack of a binding site for a transcriptional repressor gene.

It is well known that obese adults and children have higher plasma levels of PAI-1 than non-obese controls. Other studies have shown that high BMI, dyslipidemia, and insulin resistance are associated with high PAI-1 levels in obese adults. This is possibly because adipose tissue produces PAI-1, and increases circulating PAI-1 levels in both obese and insulin-resistant subjects. Furthermore, studies of

Table 2 Clinical and biochemical characteristics stratified by -675 4G/5G polymorphism in the PAI-1 gene.

<table>
<thead>
<tr>
<th>Variables</th>
<th>4G/4G (n = 18)</th>
<th>4G/5G (n = 70)</th>
<th>5G/5G (n = 86)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years)</strong></td>
<td>9 (6-13)</td>
<td>9 (6-12)</td>
<td>9 (6-11)</td>
<td>0.74</td>
</tr>
<tr>
<td>Gender (%)</td>
<td></td>
<td></td>
<td></td>
<td>0.39</td>
</tr>
<tr>
<td>Male</td>
<td>10 (55.56)</td>
<td>31 (44.29)</td>
<td>47 (54.65)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>8 (44.44)</td>
<td>39 (55.71)</td>
<td>39 (45.35)</td>
<td></td>
</tr>
<tr>
<td><strong>Weight (kg)</strong></td>
<td>31.85 (19.2-62.4)</td>
<td>37.75 (19.7-59.2)</td>
<td>32.1 (21-59.1)</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Height (cm)</strong></td>
<td>131.92 ± 10.56</td>
<td>133.7 ± 12.53</td>
<td>133.39 ± 11</td>
<td>0.45</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>20.5 (13.81-28.4)</td>
<td>17.55 (14.9-27.5)</td>
<td>15.4 (12.8-25.4)</td>
<td>0.22</td>
</tr>
<tr>
<td>Waist-hip-ratio</td>
<td>0.88 (0.77-1.08)</td>
<td>0.9 (0.8-1)</td>
<td>0.89 (0.8-0.97)</td>
<td>0.02</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>65 (55-89)</td>
<td>71.5 (56-90)</td>
<td>66.75 (53-90)</td>
<td>0.08</td>
</tr>
<tr>
<td>Hip circumference (cm)</td>
<td>74.5 (62-100)</td>
<td>80 (61-99)</td>
<td>74.15 (63-96)</td>
<td>0.27</td>
</tr>
<tr>
<td>Arm circumference (cm)</td>
<td>21 (15-32)</td>
<td>23 (16-39)</td>
<td>20.5 (17-28)</td>
<td>0.13</td>
</tr>
<tr>
<td>Biceps skinfold (mm)</td>
<td>16.36 ± 4.76</td>
<td>16.07 ± 4.70</td>
<td>15.13 ± 4.55</td>
<td>0.94</td>
</tr>
<tr>
<td>Triceps skinfold (mm)</td>
<td>15.25 (9-28.5)</td>
<td>16 (8.5-21.5)</td>
<td>14 (8-21.5)</td>
<td>0.3</td>
</tr>
<tr>
<td>Subscapular skinfold (mm)</td>
<td>11 (5-26)</td>
<td>16 (6-22.5)</td>
<td>12.5 (6-22)</td>
<td>0.09</td>
</tr>
<tr>
<td>Suprailliac skinfold (mm)</td>
<td>18.14 ± 6.24</td>
<td>18.58 ± 5.09</td>
<td>17.80 ± 5.96</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Glucose (mg/dL)</strong></td>
<td>97.5 (81-118)</td>
<td>95 (70-111)</td>
<td>97 (75-107)</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>Insulin (µU/mL)</strong></td>
<td>4.6 (0.55-53.58)</td>
<td>8.4 (0.79-22.1)</td>
<td>6.25 (1.72-24.97)</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>HOMA-IR</strong></td>
<td>1.12 (0.11-12.83)</td>
<td>1.95 (0.19-4.88)</td>
<td>1.42 (0.33-6.04)</td>
<td>0.16</td>
</tr>
</tbody>
</table>

**Insulin resistance**

Yes: 5 (27.78) 28 (40) 24 (27.91)

No: 13 (72.22) 42 (60) 62 (72.09)

BMI, body mass index; HOMA-IR, homeostasis model assessment for insulin resistance; PAI-1, plasminogen activator inhibitor 1; SD, standard deviation.

a Data provided as median and 5th and 95th percentiles. Kruskal-Wallis test.
b Data provided as n and percentage. Chi-squared test.
c Data provided as mean±SD. ANOVA test.

Table 3 Effect of -675 4G/5G polymorphism on body measures.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Model without adjusted</th>
<th>Model adjusteda</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (CI 95%)</td>
<td>R²</td>
</tr>
<tr>
<td>Waist-hip-ratio</td>
<td>0.02 (0.004-0.04)</td>
<td>0.03</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>3.74 (0.09-7.39)</td>
<td>0.02</td>
</tr>
<tr>
<td>Subscapular skinfold (mm)</td>
<td>1.81 (0.71-3.54)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

a Adjusted by age and gender. 95% CI, 95% confidence interval.
PAI-1 knockout mice have shown an effect of PAI-1 on weight gain and increased adipose cellularity associated with high-fat die.5 Besides disruption of the PAI-1 gene reducing the adiposity of the obese ob/ob mice, this suggests that the PAI-1 gene can control fat mass. Although the mechanism of action is not yet known, it has been proposed that the proliferation of adipocytes may be related to the expression of genes, such as tumor necrosis factor alpha (TNF-α), transforming growth factor beta (TGF-β), leptin, and insulin.14

In the present study, the -675 4G/5G polymorphism in the PAI-1 gene was associated with increased body adiposity, and not with insulin resistance. This is probably because the -675 4G/5G polymorphism in the PAI-1 gene does not contribute directly to the development of insulin resistance in normal-weight and obese children; as the insulin resistance may be of multifactorial origin, in which environmental and genetic factors are involved. That could be influenced by other polymorphisms related to alterations in energetic metabolism, and to the development of obesity in children. Although the data suggest that the -675 4G/5G polymorphism in PAI-1 gene is linked to body adiposity, further studies are needed to clarify this role.

Even though in this study an association between genotype 4G/5G polymorphism in the PAI-1 gene and body adiposity was found, a limitation of the present study is that PAI-1 plasma levels were not measured; thus, the association of the genotypes with PAI-1 levels remains uncertain in this population. Future studies in Mexican children are necessary to determine this parameter.

In summary, the -675 4G/5G genotype of the PAI-1 gene was associated with measures of body adiposity but not with insulin resistance, which suggests that this genotype may confer susceptibility for obesity in Mexican children.

Funding

This research was supported by grants No. 106734 from the Fondo de Investigación Básica SEP-CONACYT 2008-01 and No. 147778 from the Fondo Mixto CONACYT-Gobierno del Estado de Guerrero 2010-01.

Conflicts of interest

The authors declare no conflicts of interest.

References

